Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06989723 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This exploratory study will assess the efficacy of combined pioglitazone and empagliflozin therapy in improving hepatic and metabolic outcomes in patients with type 2 diabetes mellitus and metabolic dysfunction-associated fatty liver disease (MAFLD). Although each agent has shown beneficial effects individually, evidence on their combined impact on liver health is scarce. This study seeks to determine whether the combination therapy yields additive improvements in hepatic steatosis, inflammation, and fibrosis, potentially offering a new therapeutic strategy for diabetic patients with fatty liver disease.
Trial Details
NCT Number NCT06989723
Lead Sponsor Seoul National University Bundang Hospital
Collaborators: Celltrion
Conditions
(from sponsor)		 Type 2 Diabetes, Fatty Liver
Related terms Diabetes Mellitus, Type 2, Fatty Liver
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov